Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Yuhudie Quban Gao for melasma
ChiCTR2400081321Phase 3Not yet recruiting
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
- Start
- Feb 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Yuhudie Melasma Ointment in melasma (2 arms), sponsored by Beijing Hospital of Traditional Chinese Medicine. Primary endpoint: MASI score reduction rate at week 12. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
Yuhudie Melasma Ointment
03
Conditions
melasma
Beyond the preview
Go deeper on ChiCTR2400081321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081321.